Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.29 USD | +1.47% | +21.02% | +76.33% |
Apr. 23 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
Apr. 22 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.33% | 1.78B | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Wedbush Lowers Edgewise Therapeutics' PT to $23 From $27, Sees 2024 as 'Critical' Year; Keeps Outperform Rating